A nurse is performing an admission assessment for a client who is to undergo a colonoscopy. The client informs the nurse that he took his prescribed medications before coming to the clinic. Which of the following medications is the priority to report to the provider?
A.
Metoprolol
B.
Clopidogrel
C.
Metformin
D.
Digoxin
The Correct Answer and Explanation is:
In the context of a client preparing for a colonoscopy, the priority medication to report to the provider is B. Clopidogrel.
Explanation:
Clopidogrel is an antiplatelet medication commonly used to prevent blood clots. It is crucial for patients who have a history of cardiovascular events, such as myocardial infarction or stroke. Since colonoscopy involves insertion of a scope through the rectum into the colon, there is a risk of bleeding, especially if any polyps are removed or biopsies are taken. Antiplatelet medications like clopidogrel can increase the risk of bleeding complications due to their effect on inhibiting platelet aggregation.
Metoprolol is a beta-blocker used to manage hypertension and other cardiovascular conditions. While it is important to monitor blood pressure and heart rate, metoprolol is generally less of an immediate concern in the context of a colonoscopy compared to clopidogrel. The main issue with metoprolol would be ensuring that the client’s blood pressure is well-controlled, but it does not have a direct impact on bleeding risk.
Metformin is a medication used to manage type 2 diabetes by improving insulin sensitivity and reducing blood glucose levels. While it is essential to manage blood glucose levels, metformin is not directly associated with increased bleeding risk during procedures. However, the client should be advised to withhold metformin on the day of the procedure to prevent lactic acidosis, particularly if contrast dye is used.
Digoxin is a cardiac glycoside used to treat heart failure and certain arrhythmias. It has a narrow therapeutic range, so monitoring levels is crucial, but it is less likely to cause bleeding complications compared to clopidogrel. The primary concern with digoxin would be its effect on cardiac function rather than bleeding.
Given these considerations, clopidogrel’s role in increasing bleeding risk makes it the priority medication to report to the provider. The provider may need to consider adjusting or temporarily discontinuing clopidogrel before the colonoscopy to reduce the risk of bleeding complications.